Medical collage with scans, tissue, blood, anatomy, and treatment cues

Master cancer immunotherapy reference

Immunotherapy for Cancers

Start here, then go to the cancer-specific page. Immunotherapy can be standard treatment, biomarker-selected treatment, later-line treatment, or clinical-trial research depending on the exact cancer, stage, biomarkers, prior therapy, and local funding.

Browse cancer types ClinicalTrials.gov

How to read the network

Current status by cancer type

Strong current-use or major standard-care role

Bladder Cancer, Blood Cancer, Breast Cancer, Esophageal Cancer, Kidney Cancer, Leukemia, Lung Cancer, Lymphoma, Melanoma, Multiple Myeloma, Stomach Cancer

Selected use, subtype-specific use, or biomarker-driven use

Colon Cancer, Oral Cancer, Ovarian Cancer, Prostate Cancer, Rectal Cancer, Skin Cancer, Throat / Head and Neck Cancer, Thyroid Cancer

Mainly clinical-trial or frontier research focus

Bone Cancer, Brain Cancer, Glioma, Pancreatic Cancer, Testicular Cancer

Patient language access

Cancer Immunotherapy first, then the full hub.

Cancer Immunotherapy

Choose a language to open this cancer immunotherapy hub through Google Translate. Automated translation is for orientation only; clinical decisions still need an oncologist, interpreter, and local treatment advice.

Cancer-specific sites

Choose a cancer type

Bladder Cancer Immunotherapy for Bladder Cancer Strong current-use or major standard-care role Blood Cancer Immunotherapy for Blood Cancer Strong current-use or major standard-care role Bone Cancer Immunotherapy for Bone Cancer Mainly clinical-trial or frontier research focus Brain Cancer Immunotherapy for Brain Cancer Mainly clinical-trial or frontier research focus Breast Cancer Immunotherapy for Breast Cancer Strong current-use or major standard-care role Colon Cancer Immunotherapy for Colon Cancer Selected use, subtype-specific use, or biomarker-driven use Esophageal Cancer Immunotherapy for Esophageal Cancer Strong current-use or major standard-care role Glioma Immunotherapy for Glioma Mainly clinical-trial or frontier research focus Kidney Cancer Immunotherapy for Kidney Cancer Strong current-use or major standard-care role Leukemia Immunotherapy for Leukemia Strong current-use or major standard-care role Lung Cancer Immunotherapy for Lung Cancer Strong current-use or major standard-care role Lymphoma Immunotherapy for Lymphoma Strong current-use or major standard-care role Melanoma Immunotherapy for Melanoma Strong current-use or major standard-care role Multiple Myeloma Immunotherapy for Myeloma Strong current-use or major standard-care role Oral Cancer Immunotherapy for Oral Cancer Selected use, subtype-specific use, or biomarker-driven use Ovarian Cancer Immunotherapy for Ovarian Cancer Selected use, subtype-specific use, or biomarker-driven use Pancreatic Cancer Immunotherapy for Pancreatic Cancer Mainly clinical-trial or frontier research focus Prostate Cancer Immunotherapy for Prostate Cancer Selected use, subtype-specific use, or biomarker-driven use Rectal Cancer Immunotherapy for Rectal Cancer Selected use, subtype-specific use, or biomarker-driven use Skin Cancer Immunotherapy for Skin Cancer Selected use, subtype-specific use, or biomarker-driven use Stomach Cancer Immunotherapy for Stomach Cancer Strong current-use or major standard-care role Testicular Cancer Immunotherapy for Testicular Cancer Mainly clinical-trial or frontier research focus Throat / Head and Neck Cancer Immunotherapy for Throat Cancer Selected use, subtype-specific use, or biomarker-driven use Thyroid Cancer Immunotherapy for Thyroid Cancer Selected use, subtype-specific use, or biomarker-driven use

Trials and evidence

Reference starting points

NCI: Immunotherapy NCI: CAR T cells ClinicalTrials.gov PubMed reviews

Cost and coverage

Approval is not the same as funding

Immunotherapy access changes frequently. A drug can be approved but not publicly funded, funded only for a precise biomarker or stage, or covered only after standard treatments. Patients should confirm the latest local rules with the treating oncologist, cancer center pharmacist, insurer, public formulary, or hospital financial navigator.